• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ocular Therapeutix Inc.

    12/28/23 4:17:19 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUL alert in real time by email
    SC 13G 1 tm2332531d2_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Ocular Therapeutix, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    67576A 10 0

     

    (CUSIP Number)

     

    December 18, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

    x

    ¨

    Rule 13d-1(b)

    Rule 13d-1(c)

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 67576A 10 0 Page 2 of 17

     

    1.

    Names of Reporting Persons

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the Securities and Exchange Commission (the “SEC”) on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 3 of 17

     

    1.

    Names of Reporting Persons

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 4 of 17

     

    1.

    Names of Reporting Persons

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 5 of 17

     

    1.

    Names of Reporting Persons

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 6 of 17

     

    1.

    Names of Reporting Persons

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 7 of 17

     

    1.

    Names of Reporting Persons

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 8 of 17

     

    1.

    Names of Reporting Persons

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 9 of 17

     

    Item 1.    
      (a)

    Name of Issuer

     

    Ocular Therapeutix, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

     

    24 Crosby Drive, Bedford, MA 01730

         
    Item 2.    
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

         
      (b)

    Address of Principal Business Office or, if none, Residence

     

    New York Office:                        Palo Alto Office:

     

    7 Bryant Park                                3340 Hillview Avenue

    23rd Floor                                       Palo Alto, CA 94304

    New York, NY 10018

         
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.0001 par value

         
      (e)

    CUSIP Number

     

    67576A 10 0

         
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

     

     

     

    CUSIP No. 67576A 10 0 Page 10 of 17

     

    Item 4. Ownership  
         
      (a) Amount beneficially owned:  
           
          Venrock Healthcare Capital Partners III, L.P. 7,775,760  (1)  
          VHCP Co-Investment Holdings III, LLC 7,775,760  (1)  
          Venrock Healthcare Capital Partners EG, L.P. 7,775,760  (1)  
          VHCP Management III, LLC 7,775,760  (1)  
          VHCP Management EG, LLC 7,775,760  (1)  
          Nimish Shah 7,775,760  (1)  
          Bong Koh 7,775,760  (1)  
             
      (b) Percent of class:  
           
          Venrock Healthcare Capital Partners III, L.P. 6.8%  (2)  
          VHCP Co-Investment Holdings III, LLC 6.8%  (2)  
          Venrock Healthcare Capital Partners EG, L.P. 6.8%  (2)  
          VHCP Management III, LLC 6.8%  (2)  
          VHCP Management EG, LLC 6.8%  (2)  
          Nimish Shah 6.8%  (2)  
          Bong Koh 6.8%  (2)  
             
      (c) Number of shares as to which the person has:  
           
        (i) Sole power to vote or to direct the vote:  
           
          Venrock Healthcare Capital Partners III, L.P. 0  
          VHCP Co-Investment Holdings III, LLC 0  
          Venrock Healthcare Capital Partners EG, L.P. 0  
          VHCP Management III, LLC 0  
          VHCP Management EG, LLC 0  
          Nimish Shah 0  
          Bong Koh 0  
             
        (ii) Shared power to vote or to direct the vote:  
           
          Venrock Healthcare Capital Partners III, L.P. 7,775,760  (1)  
          VHCP Co-Investment Holdings III, LLC 7,775,760  (1)  
          Venrock Healthcare Capital Partners EG, L.P. 7,775,760  (1)  
          VHCP Management III, LLC 7,775,760  (1)  
          VHCP Management EG, LLC 7,775,760  (1)  
          Nimish Shah 7,775,760  (1)  
          Bong Koh 7,775,760  (1)  

     

     

     

     

    CUSIP No. 67576A 10 0 Page 11 of 17

     

        (iii) Sole power to dispose or to direct the disposition of:  
           
          Venrock Healthcare Capital Partners III, L.P. 0  
          VHCP Co-Investment Holdings III, LLC 0  
          Venrock Healthcare Capital Partners EG, L.P. 0  
          VHCP Management III, LLC 0  
          VHCP Management EG, LLC 0  
          Nimish Shah 0  
          Bong Koh 0  
             
        (iv) Shared power to dispose or to direct the disposition of:  
           
          Venrock Healthcare Capital Partners III, L.P. 7,775,760  (1)  
          VHCP Co-Investment Holdings III, LLC 7,775,760  (1)  
          Venrock Healthcare Capital Partners EG, L.P. 7,775,760  (1)  
          VHCP Management III, LLC 7,775,760  (1)  
          VHCP Management EG, LLC 7,775,760  (1)  
          Nimish Shah 7,775,760  (1)  
          Bong Koh 7,775,760  (1)  

     

      (1)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

      (2)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable

     

     

     

     

    CUSIP No. 67576A 10 0 Page 12 of 17

     

    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 13 of 17

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 28, 2023

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact      
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. 67576A 10 0 Page 14 of 17

     

    EXHIBITS

     

    A: Joint Filing Agreement
       
    B: Power of Attorney for Nimish Shah
       
    C: Power of Attorney for Bong Koh

     

     

     

     

    CUSIP No. 67576A 10 0 Page 15 of 17

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Ocular Therapeutix, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 28th day of December, 2023.

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. 67576A 10 0 Page 16 of 17

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28th day of December, 2023.

     

    /s/ Nimish Shah  

     

     

     

     

    CUSIP No. 67576A 10 0 Page 17 of 17

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28th day of December, 2023.

     

    /s/ Bong Koh  

     

     

     

    Get the next $OCUL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCUL

    DatePrice TargetRatingAnalyst
    9/15/2025$21.00Buy
    Chardan Capital Markets
    4/8/2025Outperform
    William Blair
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    3/11/2025$15.00Buy
    Needham
    10/16/2024Sector Outperform
    Scotiabank
    6/20/2024$7.00 → $11.00Hold → Buy
    TD Cowen
    5/31/2024$15.00Overweight
    Piper Sandler
    2/9/2024$15.00Buy
    BofA Securities
    More analyst ratings

    $OCUL
    SEC Filings

    View All

    SEC Form 10-Q filed by Ocular Therapeutix Inc.

    10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    5/5/26 7:28:34 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    5/5/26 7:06:45 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Ocular Therapeutix Inc.

    DEFA14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    4/30/26 5:23:14 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    5/12/25 8:50:46 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summer Road Llc bought $7,000,000 worth of shares (930,851 units at $7.52) (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/27/24 4:43:51 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to seven newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of June 1, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 51,775 shares of Ocular's comm

    6/5/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

    BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada. Clinical Trials at the Summit (CTS) 2026 Presentation Details: Fireside Chat with Wiley Chambers, MDFireside Date/Time: Friday, June 12, 2026, 8:05 – 8:30 PM PTModerators: Jeffrey S. Heier, MD, Chief Scientific Officer; Peter K. Kaiser, MD, Chief Development Officer Presentation Title: OTX-TKI: Overview of ScienceSession: Clinical Trials Addressing nAMD, DME, and DRPresentation D

    6/4/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Host Investor Day on June 17, 2026

    In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M. Moshfeghi, MD  Company to highlight AXPAXLI™ wet AMD NDA submission plan, updates on SOL-R, SOL-X, and registrational diabetic retinopathy program, and an overview of the planned commercialization approach for AXPAXLI, if approved The live event will take place in New York City on June 17, 2026, starting at 2:00 PM ET BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, will host

    6/2/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Waheed Nadia sold $122,628 worth of shares (14,828 units at $8.27), decreasing direct ownership by 5% to 300,079 units (SEC Form 4) (tax liability)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    6/5/26 4:01:07 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Dugel Pravin received a gift of 394,696 shares, sold $173,479 worth of shares (21,156 units at $8.20) and gifted 394,696 shares, decreasing direct ownership by 0.81% to 2,597,170 units (SEC Form 4) to cover taxes

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    5/28/26 4:08:06 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Kaiser Peter sold $24,329 worth of shares (2,967 units at $8.20), decreasing direct ownership by 1% to 266,141 units (SEC Form 4) to satisfy withholding obligation

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    5/28/26 4:07:29 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Ocular Therapeutix with a new price target

    Chardan Capital Markets initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $21.00

    9/15/25 8:09:22 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Ocular Therapeutix

    William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform

    4/8/25 9:29:59 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target

    RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00

    3/18/25 7:53:57 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Financials

    Live finance-specific insights

    View All

    Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

    Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF SOL-1 Week 52 data presentations held at Macula Society and VBS meetings reinforce AXPAXLI's unmatched durability and sustained disease control data in wet AMD Commercial preparedness plans accelerated as Ocular intends to submit AXPAXLI NDA based on SOL-1 Week 52 data, subject to ongoing formal discussions with the U.S. FDA SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline read

    5/5/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

    BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026. Conference Call and Webcast Information: Date: Tuesday, May 5, 2026 at 8:00 AM ETParticipant Dial-In (U.S.): 1-800-343-4136Participant Dial-In (International): 1-203-518-9843Conference ID: OCULAR (required for entry)Webcast Access: Please click here The live and archived webcast can also be access

    4/28/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

    Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Soc

    2/23/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Leadership Updates

    Live Leadership Updates

    View All

    Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

    Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success

    1/21/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix® to Host Investor Day on June 13, 2024

    Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

    6/5/24 7:30:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports First Quarter 2024 Results

    Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

    5/7/24 4:05:00 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ocular Therapeutix Inc.

    SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 9:37:26 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/12/24 4:49:23 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care